Drug does not cut heart risk in diabetes patients with CKD, study finds

11/11/2013 | PhysiciansBriefing.com

A Dutch study in the New England Journal of Medicine found bardoxolone methyl was not effective in reducing the odds of cardiovascular death or end-stage renal disease in type 2 diabetes patients with stage 4 chronic kidney disease. Researchers examined 2,185 participants at a median follow-up of nine months and found more patients in the intervention arm were either hospitalized for heart failure or had died of the condition than in the placebo group.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
Nationwide, SL_Nationwide
Finance Manager - ENT
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA